...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Australian and New Zealand journal of psychiatry >Mirtazapine induced mania in a woman with major depression in the absence of features of bipolarity.
【24h】

Mirtazapine induced mania in a woman with major depression in the absence of features of bipolarity.

机译：在没有躁郁症特征的情况下，米氮平在患有严重抑郁症的女性中引起躁狂。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The existing literature indicates that a manic switch with mirtazapine is a rare event, occurring in 0.25% of all mirtazapine-treated patients [1]. Mirtazapine is a dual acting tetracyclic piperazinoazepine compound, with therapeutic effects thought to be through inhibition of alpha_2-adrenergic receptors, thus increasing the firing rates of both noradrenergic and serotonergic neurons and post-synaptic blockade of 5-HT 2 and 3 receptors [1,2]. Manic switch has been reported in an adult with unipolar depression with higher doses of mirtazapine (> 60 mg/day) and in a woman with vascular risk factors (diabetes mellitus and hypertension) presenting as late life depression [3,4]. Mirtazapine-induced mania has also been reported in a case with depression comorbid with stroke involving the right frontal lobe, and in an adolescent with unipolar depression [5,6]. However, we report a case of manic switch with use of mirtazapine at the therapeutic dose.
机译：现有文献表明，用米氮平进行躁狂转换是罕见的事件，在所有经米氮平治疗的患者中占0.25％[1]。米氮平是一种双作用的四环哌嗪氮杂卓化合物，据认为具有治疗作用，其作用是通过抑制α_2-肾上腺素能受体，从而提高去甲肾上腺素能神经元和5-羟色胺能神经元的放电率，以及突触后对5-HT 2和3受体的阻断[1， 2]。据报道，患有单极性抑郁症的成年人服用米氮平的剂量较高（> 60 mg /天），而患有血管性危险因素（糖尿病和高血压）的女性则表现为晚期抑郁症[3,4]。在患有右额叶卒中并发抑郁的青少年以及单相抑郁症的青少年中，也曾报道过米氮平诱发的躁狂症[5,6]。但是，我们报告了以治疗剂量使用米氮平引起的躁狂转换病例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号